September 12, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces that it has initiated the process of obtaining a secondary listing on the Australian Stock Exchange (ASX) and expects this process to be completed by calendar Q1 2018. The Company has successfully completed the due diligence and corporate review requirements of the exchange and will now move forward in filing for approval.
In correlation with this dual listing, the company announces a strategic investment of $1,003,104 CDN through the issuance of 4,012,414 common shares at $0.25 with a full 2-year warrant at $.75 with a 30-day acceleration clause if the stock trades above $1.00 for 10 consecutive days. This capital will be used to fund the operational expansion into Australia and certain regions of South East Asia.
Marcos Agramont, CEO of Isodiol International Inc, stated “We are excited to be expanding our footprint into Australia which we see as the gateway into Asia. We have seen incredible traction of our flagship product Isoderm™ in Latin America and we envision similar traction in the Australasia region. Obtaining a public listing on the ASX allows us to solidify our footprint, as well as access to the capital markets that a company would not have being based in Canada. This industry is in its infancy stage in Australia and we believe we can become the leaders in innovation and product development within the region. This listing will complement our current listings on the Canadian Stock Exchange (CSE), the OTC in the US and Germany.”
The Company also announces August 2017 unaudited revenue of its wholly owned subsidiary, Iso International LLC, of $1,410,743 USD. Marcos Agramont stated, “As we continue to expand our operations into international markets, maintaining strong domestic revenues in North America has been a focus for us.”
The Company will provide additional information on its Australasia commercialization strategy as it is developed.
About Isodiol International Inc.<
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products./p>
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a 99%+ pure pharmaceutical grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.